

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

## Complete if Known

Application Number	10/632,187
Filing Date	July 30, 2003
First Named Inventor	Jürgen Engel
Art Unit	1628
Examiner Name	Shirley Gembeh
Attorney Docket Number	ZEN-015-NP (Old 103832-477-NP)

Sheet 1 of 6

## NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		ASCO Abstract 2006 - Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings (Post-Meeting Edition)m Vol. 24, No. 18S (June 20 Supplement), 2006.	
		ASCO Abstract 2009 - Journal of Clinical Oncology, 2009 ASCO Annual Meeting Proceedings (Post-Meeting Edition)m Vol. 27, No. 15S (May 20 Supplement), 2009:4081.	
		AYALA, GUSTAVO, et al., Bortezomib-Mediated Inhibition of Steroid Receptor Coactivator-3 Degradation Leads to Activated Akt, Clin Cancer Res, November 15, 2008, 7511-7518, 14(22).	
		CATLEY LAURENCE, et al., Alkyl Phospholipid Perifosine Induces Myeloid Hyperplasia in a Murine Myeloma Model, Experimental Hematology, 35 (2007), 1038-1046.	
		CHIARINI, F., et al., The novel Akt Inhibitor, Perifosine, Induces Caspase-Dependent Apoptosis and Downregulates P-glycoprotein Expression in Multidrug-Resistant Human T-acute Leukemia Cells by a JNK-dependent Mechanism, Leukemia (2008) 22, 1106-1116.	
		CIRSTEA, DIANA, et al., Dual Inhibition of Akt/Mammalian Target of Rapamycin Pathway by Nanoparticle Albumin-Bound-Rapamycin and Perifosine Induces Antitumor Activity in Multiple Myeloma, Mol Cancer Ther, April 2010, 963-975, 9(4).	
		CRUL, M., et al. Phase I and Pharmacological Study of Daily Oral Administration of Perifosine (D-21266) in Patients with Advanced Solid Tumours, European Journal of Cancer, 38 (2002), 1615-1621.	
		DASMAHAPATRA GIRIJA P., et al., In vitro Combination Treatment with Perifosine and UCN-01 Demonstrates Synergism Against Prostate (PC-3) and Lung (A549) Epithelial Adenocarcinoma Cell Lines, Clin Cancer Res, August 1, 2004, 5242-5252, Vol. 10.	
		DAVID, E., et al., Perifosine Synergistically Enhances TRAIL-Induced Myeloma Cell Apoptosis via Up-Regulation of Death Receptors, Clin Cancer Res 2008;14(16) August 15, 2008, 5090-5098.	
		DOGAN, S. SERDAR, Ocular Side Effects Associated with Imatinib Mesylate and Perifosine for Gastrointestinal Stromal Tumor, Hematol Oncol. Clin N Am, 23 (2009) 109-114.	

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)		<b>Complete if Known</b>	
		<b>Application Number</b>	10/632,187
		<b>Filing Date</b>	July 30, 2003
		<b>First Named Inventor</b>	Jürgen Engel
		<b>Art Unit</b>	1628
		<b>Examiner Name</b>	Shirley Gembeh
<b>Attorney Docket Number</b>	ZEN-015-NP (Old 103832-477-NP)		

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		ELLIS, MATTHEW J., et al., "PIKING" the Winner for Phosphatidylinositol 3-Kinase Inhibitors in ErbB2-Positive Breast Cancer: Let's Not "PTENED" It's Easy!, Clin Cancer Res, October 1, 2007, 5661-5662, 13(19).	
		ENGEL, JÖRG B., et al., Induction of Programmed Cell Death By Inhibition of AKT with the Alkylphosphocholine Perifosine in In Vitro Models of Platinum Sensitive and Resistant Ovarian Cancers, Arch Gynecol Obstet, doi:10.1007/s00404-010-1457-6; published online April 20, 2010.	
		ENGEL, JÖRG B., et al., Perifosine Inhibits Growth of Human Experimental Endometrial Cancers By Blockade of AKT Phosphorylation, Eur J. Obstet. Gynecol (2008), doi:10.1016/j.ejogrb.2008.06.007.	
		ERNST, D. SCOTT, et al. Phase II Study of Perifosine in Previously Untreated Patients with Metastatic Melanoma, Investigational New Drugs, 23:569-576, 2005.	
		FESTUCCIA, CLAUDIO, et al., Akt Down-Modulation Induces Apoptosis of Human Prostate Cancer Cells and Synergizes with EGFR Tyrosine Kinase Inhibitors, The Prostate, 58:965-974 (2008).	
		FLORYK, DANIEL, et al., Perifosine Induces Differentiation and Cell Death in Prostate Cancer Cells, Cancer Letters, 266 (2008) 216-226.	
		FOMCHENKO, ELENA I., et al., Mouse Models of Brain Tumors and Their Applications in Preclinical Trials, Clin Cancer Res., 2006;12(18) September 15, 2006; 5288-5297.	
		FU, LEI, et al., Perifosine Inhibits Mammalian Target of Rapamycin Signaling through Facilitating Degradation of Major Components in the mTOR Axis and Induces Autophagy, Cancer Res, December 1, 2009, 8967-8976, 69(23).	
		GAJATE, CONSUELO, et al., Edelfosine and Perifosine Induce Selective Apoptosis in Multiple Myeloma by Recruitment of Death Receptors and Downstream Signaling Molecules into Lipids Rafts, Blood, January 15, 2007, 711-719, Vol. 109, Number 2.	
		GILLS, JOELL, et al., Perifosine: Update on a Novel Akt Inhibitor, Current Oncology Reports-Evolving Therapies, 11:102-110.	

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 3 of 6

## Complete if Known

Application Number	10/632,187
Filing Date	July 30, 2003
First Named Inventor	Jürgen Engel
Art Unit	1628
Examiner Name	Shirley Gembeh
Attorney Docket Number	ZEN-015-NP (Old 103832-477-NP)

## NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		HARVEY, R. DONALD, et al., P13 Kinase/AKT Pathway as a Therapeutic Target in Multiple Myeloma, Future Oncol., (2007) 3(6), 639-647.	
		HIDESHIMA, TERU, et al., Perifosine, An Oral Bioactive Novel Alkylphospholipid, Inhibits Akt and Induces In Vitro and In Vivo Cytotoxicity in Human Multiple Myeloma Cells, Blood First Edition Paper, January 17, 2006, 1-34, doi 10.1182/blood-2005-08-3434.	
		HIDESHIMA, TERU, et al., Inhibition of Akt Induces Significant Downregulation of Survivin and Cytotoxicity in Human Multiple Myeloma Cells, British Journal of Haematology, 2007, 138, 783-791.	
		HUSTON, ALISSA, et al., Targeting and Heat Shock Protein 90 Produces Synergistic Multiple Myeloma Cell Cytotoxicity in the Bone Marrow Microenvironment, Clin Cancer Res, February 1, 2008, 865-874, 14(3).	
		JENDROSSEK, V., et al., Membrane Targeted Anticancer Drugs: Potent Inducers of Apoptosis and Putative Radiosensitizers, Curr. Med. Chem. - Anti-Cancer Agents, 2003, 3, 343-353.	
		KNOWLING, M., et al., A Phase II Study of Perifosine (D-21226) in Patients with Previously Untreated Metastatic or Locally Advanced Soft Tissue Sarcoma: A National Cancer Institute of Canada Clinical Trials Group Trial, Invest New Drugs, (2006), 24:435-439.	
		KODACH, LIUDMILA L., vilacein Synergistically Increases 5-fluorouracil Cytotoxicity, Induces Apoptosis and Inhibits Akt-mediated Signal Transduction in Human Colorectal Cancer Cells, Carcinogenesis, 2006, Vol. 27, No. 3, 508-516.	
		KONDAPAKA, SUDHIR B., Perifosine, A Novel Alkylphospholipid, Inhibits Protein Kinase B Activation., Molecular Cancer Therapeutics, 1093-1103.	
		KONSTANTINOV, SPIRO M., et al., BCR-ABL Influences the Antileukaemic Efficacy of Alkylphosphocholines, British Journal of Haematology, 1999, 107, 365-374.	
		KONSTANTINOV, SPIRO M., et al., Human Urinary Bladder Carcinoma Cell Lines Respond to Treatment with Alkylphosphocholines, Cancer Letters, 1999, 144, 153-160.	

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Substitute for form 1449/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 4 of 6

## Complete if Known

Application Number	10/632,187
Filing Date	July 30, 2003
First Named Inventor	Jürgen Engel
Art Unit	1628
Examiner Name	Shirley Gembel
Attorney Docket Number	ZEN-015-NP (Old 103832-477-NP)

## NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		KONSTANTINOV, SPIRO M., et al., Alkylphosphocholines: Effects on Human Leukemic Cell Lines and Normal Bone Marrow Cells, Int. J. Cancer, 1998, 77, 778-786.	
		KUMAR, ANIL, et al., The Alkylphospholipid Perifosine Induces Apoptosis and p21-Mediated Cell Cycle Arrest in Medulloblastoma, Mol Cancer Res, November 2009, 1813-1821, 7(11).	
		LEIGHL, NATASHA B., et al., A Phase 2 Study of Perifosine in Advanced or Metastatic Breast Cancer, Breast Cancer Res Treat (2008), 108:87-92.	
		LELEU, XAVIER, et al., Targeting NF-κB in Waldenström Macroglobulinemia, Blood, May 15, 2008, 111(10), 5068-5077.	
		LI, X., et al., Enhancement of Antitumor Activity of the Anti-EGF Receptor Monoclonal Antibody Cetuximab/C225 by Perifosine in PTEN-deficient Cancer Cells, Oncogen, (2005), 1-11.	
		LOPICCOLO, JACLYN, et al., Targeting the P13K/Akt/mTOR Pathway: Effective Combinations and Clinical Considerations, Drug Resistance Updates, 11 (2008) 32-50.	
		MITSIADIS, CONSTANTIN S., et al., Emerging Treatments for Multiple Myeloma: Beyond Immunomodulatory Drugs and Bortezomib, Seminars in Hematology, April 2009, Vol. 46, No. 2, 166-175.	
		MOMOTA, HIROYUKI, et al., Perifosine Inhibits Multiple Signaling Pathways in Glial Progenitors and Cooperates With Temozolomide to Arrest Cell Proliferation in Gliomas In Vivo, Cancer Res, August 15, 2005, 65(16), 7429-7435.	
		NELSON, EC, et al., Inhibition of Akt Pathways in the Treatment of Prostate Cancer, Prostate Cancer and Prostatic Diseases, (2007), 10, 331-339.	
		NYAKERN, MARIA, et al., Synergistic Induction of Apoptosis in Human Leukemia T Cells by the Akt Inhibitor Perifosine and Etoposide Through Activation of Intrinsic and Fas-mediated Extrinsic Cell Death Pathways, Mol Cancer Ther, June 2006, 5(6), 1559-1570.	

Examiner  
Signature

Date  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>		<b>Complete if Known</b>	
		<b>Application Number</b>	10/632,187
		<b>Filing Date</b>	July 30, 2003
		<b>First Named Inventor</b>	Jürgen Engel
		<b>Art Unit</b>	1628
		<b>Examiner Name</b>	Shirley Gembeh
<b>Sheet</b>	5	<b>of</b>	6
		<b>Attorney Docket Number</b>	ZEN-015-NP (Old 103832-477-NP)

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	† <sup>2</sup>
		PAPA, V., et al., Proapoptotic Activity and Chemosensitizing Effect of the Novel Akt Inhibitor Perifosine in Acute Myelogenous Leukemia Cells, <i>Leukemia</i> , (2008), 22, 147-160.	
		PATEL, VYOMESH, Perifosine, A Novel Alkylphospholipid, Induces p21WAF1 Expression in Squamous Carcinoma Cells Through a P53-independent Pathway, Leading to Loss in Cyclin-dependent Kinase Activity and Cell Cycle Arrest, <i>Cancer Research</i> , 62, 1401-1409, 2002.	
		PORTA, CAMILLO, et al., Phosphatidylinositol-3-Kinase/Akt Signaling Pathway and Kidney Cancer, and the therapeutic Potential of Phosphatidylinositol-3-Kinase/Akt Inhibitors, <i>The Journal of Urology</i> , December 2009, Vol. 182, 2569-2577.	
		RAHMANI, MOHAMED, et al., Coadministration of Histone Deacetylase Inhibitors and Perifosine Synergistically Induces Apoptosis in Human Leukemia Cells Through Akt and ERK1/2 Inactivation and the Generation of Ceramide and Reactive Oxygen Species, <i>Cancer Res</i> , 2005, 2422-2432.	
		TAZAARI, PIER LUIGI, et al., Synergistic Proapoptotic Activity of Recombinant TRAIL Plus the Akt Inhibitor Perifosine in Acute Myelogenous Leukemia Cells, <i>Cancer Res</i> , November 15, 2008, 68 (22), 9394-9403.	
		UMMERSEN et al., A Phase I Trial of Perifosine (NSC 639966) on a Loading Dose/Maintenance Dose Schedule in Patients with Advanced Cancer, <i>Clinical Cancer Research</i> , Vol. 10, 7450-7456, November 15, 2004.	
		UNGER, CLEMENS, et al., First-Time-In-Man and Pharmacokinetic Study of Weekly Oral Perifosine in Patients with Solid Tumours, <i>European Journal of Cancer</i> , 46 (2010), 920-925.	
		VINALL, RUTH L., et al., Combination Treatment of Prostate Cancer Cell Lines with Bioactive Soy Isoflavones and Perifosine Causes Increased Growth Arrest and/or Apoptosis, <i>Clin Cancer Res</i> , October 15, 2007, 13(20), 6204-6216.	
		VINK, STEFAN R., et al., Tumor and Normal Tissue Pharmacokinetics of Perifosine, An Oral Anti-Cancer Alkylphospholipid, <i>Investigational New Drugs</i> , 23, 2005, 279-286.	
		VINK, STEFAN R., et al., Phase I and Pharmacokinetic Study of Combined Treatment With Perifosine and Radiation in Patients With Advanced Solid Tumours, <i>Radiotherapy and Oncology</i> , 80, 2006, 207-213.	

<b>Examiner Signature</b>	<b>Date Considered</b>
---------------------------	------------------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

**Complete if Known**

<b>Application Number</b>	10/632,187
<b>Filing Date</b>	July 30, 2003
<b>First Named Inventor</b>	Jürgen Engel
Art Unit	1628
<b>Examiner Name</b>	Shirley Gembeh
<b>Attorney Docket Number</b>	ZEN-015-NP (Old 103832-477-NP)

(Use as many sheets as necessary)

of 6

[illegible]Date  
Considered

1 Applicant's unique citation designation number (optional). 2 Applicant is required to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the collection of information should be directed to the USPTO, Office of Management and Enterprise Services, Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22314-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22314-1450.

*If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.*